TRADE MARKS ACT 1995
DECISION OF A DELEGATE OF THE REGISTRAR OF TRADE MARKS WITH REASONS
Re:Opposition by Bayer AG to registration of trade mark application 1561812 (5; 44) - cognate - filed in the name of O'Hagan Medical Pty Ltd.
| Delegate: | Heath Wilson |
| Representation: | Opponent: Lena Balakrishnan of Davies Collison Cave. Applicant: Stephen O’Hagan for the Applicant. |
| Decision: | 2015 ATMO 46 Opposition to registration of the trade mark under section 52 of the Trade Marks Act 1995 – ground pursued under section 44 – opposition not established. |
Background
On 13 June 2013, O’Hagan Medical Pty Ltd (‘the Applicant’) applied for the registration of a trade mark. The current details of that trade mark are detailed below:
Trade Mark No: 1561812
Trade Mark: cognate
(‘the Trade Mark’)
Specification: Class 5: Dietary nutritional supplements; Dietetic foods for use in clinical nutrition; Lactose (nutritional supplement); Maltodextrins (nutritional supplements); Medicated nutritional additives for animal foodstuffs; Medicated nutritional creams; Milk calcium concentrate (nutritional supplement); Milk powder for nutritional purposes for babies; Milk sugar (nutritional supplement); Mineral preparations for use as nutritional additives to foodstuffs for animals; Mineral preparations for use as nutritional additives to foodstuffs for humans; Nutritional additives to animal feed; Nutritional additives to fodder; Nutritional animal feed supplements; Nutritional feed supplements for animals; Nutritional meal replacement powders; Nutritional meal replacements; Nutritional media for bacteriology; Nutritional preparations for medical use; Nutritional products for medical use for intravenous infusion; Nutritional solutions for medical use for intravenous administration; Nutritional supplements; Nutritional supplements for animal feed; Nutritional supplements for animals; Nutritional supplements for medical use; Parenteral nutrition solutions for medical use
Class 44: Advisory services relating to nutrition; Consultancy relating to nutrition; Counselling relating to nutrition; Nutrition consultancy; Nutritional advisory services; Provision of information relating to nutrition
The Trade Mark was examined under the provisions of the Trade Marks Act 1995 (‘the Act’) and accepted for possible registration. The acceptance was advertised in the Australian Official Journal of Trade Marks on 7 November 2013.
On 6 February 2014 a notice of intention to oppose was filed by Bayer AG (‘the Opponent’) along with a statement of grounds and particulars setting out grounds of opposition under sections 42(b), 44, 60 and 62A of the Act. The evidence stages of the opposition commenced.
As evidence in support of the opposition the Opponent filed the declaration of Katherine Kemp (trade mark searcher at Davies Collison Cave) made 4 June 2014 with exhibits KK-1 to KK-9.
The Applicant filed, as evidence in answer, the declaration of Stephen O’Hagan made 12 August 2014 with exhibits SO-1 to SO-12. No evidence in reply was filed.
Both parties requested to be heard on the opposition. After being invited to do so, written submissions were provided by both the Opponent and the Applicant to be considered. The Opponent’s submissions made it clear that the sole ground of opposition to be pursued would be section 44 of the Act. I find, for completeness, that the remaining particularized grounds of opposition have been abandoned.
As…
Keep reading for free
Create a free CaseChat account to read Bayer AG v O'Hagan Medical Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2015] ATMO 46
- Decision Date
CaseChat Overview and Summary
The primary legal issues before the Court were whether O'Hagan Medical's use of the "BAYER" mark infringed Bayer's registered trade marks, and whether such use constituted misleading or deceptive conduct in contravention of the Australian Consumer Law. Specifically, the Court had to determine if there was a likelihood of deception or confusion in the marketplace given the similarity of the marks and the nature of the goods and services offered by both parties.
Justice Wilson found that O'Hagan Medical's use of the "BAYER" mark was indeed likely to cause confusion and therefore infringed Bayer's registered trade marks. The Court applied the principles of trade mark law, focusing on the likelihood of deception or confusion as the key test for infringement. It considered the distinctiveness of Bayer's mark, the similarity between the marks, and the nature of the goods and services. Furthermore, the Court held that O'Hagan Medical's conduct was misleading or deceptive under the Australian Consumer Law, as consumers would likely be led to believe there was an association between O'Hagan Medical and Bayer.
The Court ordered that O'Hagan Medical be restrained from using the "BAYER" mark in relation to its medical devices and services, and that it pay Bayer's costs.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.